Skip to main content

B. Levitan

Followers

3

Following

3

Co-authors

3

Public Views

University College Cork

University of Haifa

Microsoft Research

Vincenzo Bavoso

The University of Manchester

Radhika Gajjala

Bowling Green State University

George Mason University

Armando Marques-Guedes

UNL - New University of Lisbon

Koç University

Universidade de Coimbra

Independent Scholar

Interests

Uploads

Papers by B. Levitan

Case 2 best-worst scaling: For good or for bad but not for both

Journal of Choice Modelling, 2021

Abstract This paper studies the performance of case 2 best-worst scaling (BWS) when it is applied... more Abstract This paper studies the performance of case 2 best-worst scaling (BWS) when it is applied to a mix of positive and negative attributes, for example in studying treatments characterized by both benefits and harms. Intuitively, such a mix of positive and negative attributes leads to dominance. We analytically show that dominance leads to infinitely large differences between the parameter estimates for the positive versus negative attributes. The results from a simulation study confirm our analytical results: parameter values of the attributes could not be accurately recovered. When only a single positive attribute was used, even the relative ordering of the attribute level preferences was not identified. As a result, case 2 BWS can be used to elicit preferences if only good (positive) or only bad (negative) attributes are included in the choice tasks, but not for both since dominance will impact parameter estimation and therefore decision-making.

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US

Frontiers in Pharmacology, 2019

Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical ... more Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical industry, regulatory authorities, and health technology assessment (HTA) bodies/payers for use in assessments and decision-making along the medical product lifecycle (MPLC). This study aimed to identify factors and situations that influence the value of patient preference studies (PPS) in decision-making along the MPLC according to different stakeholders. Methods: Semi-structured interviews (n = 143) were conducted with six different stakeholder groups (physicians, academics, industry representatives, regulators, HTA/ payer representatives, and a combined group of patients, caregivers, and patient representatives) from seven European countries (the United Kingdom,

Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison

BMC Medical Informatics and Decision Making, 2020

BackgroundIncorporating patient preference (PP) information into decision-making has become incre... more BackgroundIncorporating patient preference (PP) information into decision-making has become increasingly important to many stakeholders. However, there is little guidance on which patient preference assessment methods, including preference exploration (qualitative) and elicitation (quantitative) methods, are most suitable for decision-making at different stages in the medical product lifecycle (MPLC). This study aimed to use an empirical approach to assess which attributes of PP assessment methods are most important, and to identify which methods are most suitable, for decision-makers’ needs during different stages in the MPLC.MethodsA four-step cumulative approach was taken: 1) Identify important criteria to appraise methods through a Q-methodology exercise, 2) Determine numerical weights to ascertain the relative importance of each criterion through an analytical hierarchy process, 3) Assess the performance of 33 PP methods by applying these weights, consulting international healt...

Stakeholder Perspectives On The Integration Of Patient Preferences In The Medical Product Life Cycle: A Multimethod Approach

Value in Health, Oct 1, 2017

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

The Patient - Patient-Centered Outcomes Research, 2019

Background Patient preferences (PP), which are investigated in PP studies using qualitative or qu... more Background Patient preferences (PP), which are investigated in PP studies using qualitative or quantitative methods, are a growing area of interest to the following stakeholders involved in the medical product lifecycle: academics, health technology assessment bodies, payers, industry, patients, physicians, and regulators. However, the use of PP in decisions along the medical product lifecycle remains limited. As the adoption of PP heavily relies on these stakeholders, knowledge of their perceptions of PP is critical. Objective This study aimed to characterize stakeholders' attitudes, needs, and concerns with respect to PP in decision making along the medical product lifecycle. Methods Semi-structured interviews (n = 143) were conducted with academics (n = 24), health technology assessment/ payer representatives (n = 24), industry representatives (n = 24), patients, caregivers and patient representatives (n = 24), physicians (n = 24), and regulators (n = 23) from seven European countries and the USA. Interviews were conducted between April and August 2017. The framework method was used to organize the data and identify themes and key findings in each interviewed stakeholder group. Results Interviewees reported being unfamiliar (43%), moderately familiar (42%), or very familiar (15%) with preference methods and studies. Interviewees across stakeholder groups generally supported the idea of using PP in the medical product lifecycle but expressed mixed opinions about the feasibility and impact of using PP in decision making. Interviewees from all stakeholder groups stressed the importance of increasing stakeholders' understanding of the concept of PP and preference methods and ensuring patients' understanding of the questions asked in PP studies. Key concerns and needs in each interviewed stakeholder group were as follows: (1) academics: investigating the validity, reliability, reproducibility, and generalizability of preference methods; (2) health technology assessment/payer representatives: developing quality criteria for evaluating PP studies and gaining insights into how to weigh them in reimbursement/payer decision making; (3) industry representatives: obtaining guidance on PP studies and recognition on the importance of PP from decision makers; (4) patients, caregivers, and patient representatives: providing an incentive and adequate information towards patients when Jorien Veldwijk and Isabelle Huys are joint last author. Disclaimer: This text and its contents reflect the PREFER project's view and not the view of the Innovative Medicines Initiative, the European Union, or the European Federation of Pharmaceutical Industries and Associations.

PCV101 Japanese Patients and Physicians Preferences for Anticoagulants Use in Atrial Fibrillation - Results From a Conjoint-Analysis Study

Value in Health, 2012

OBJECTIVES: To analyse the association between Health Related Quality of Life (HRQoL) and age, in... more OBJECTIVES: To analyse the association between Health Related Quality of Life (HRQoL) and age, in hypertensive patients and the correlation between HRQoL reported by patients and evaluated by their doctors. METHODS: Observational, cross-sectional, multi-centre study, in Primary and Specialised Care. Inclusion of 5,031 hypertensive patients, selected by quotes according to three age groups (Ͻ65, 65-79, Ն 80 years) was planned. Selection criteria were: patients whose age was over 18, diagnosed as having hypertension at least one year before inclusion and attended a follow-up visit. Information related to hypertension, basic socio-demographic and clinical data, the self-administered specific questionnaire MINICHAL for the evaluation of HRQoL (higher scores indicative of lower HRQoL), and a visual analogue scale (VAS) for the general evaluation of HRQoL (higher scores indicative of higher HRQoL) by patients and doctors, were recorded. Data of 4,346 eligible patients were included. HRQoL-age correlation was analysed by Spearman's-rho, differences among age groups by Kruskal-Wallis and patient/doctor agreement by the intraclass correlation coefficient (ICC). RESULTS: Mean age (SD) was 68.35(12.60). 38.1% of patients were under 65, 36.9% between 65 and 80 and 25.0% were over 80 years old. 54.5% were men. Mean time since diagnosis was 10.33(7.68) years. 34.2% had a family history of high blood pressure. Mean scores in MINICHAL were: State of Mind dimension 8.07(5.83), Somatic Manifestations dimension 3.24(3.06). Worsening of both dimensions was found when comparing groups of higher age (pϽ0.001) as well as significant moderate correlations of both dimensions with age (0.335, pϽ0.001; 0.397 pϽ0.001). Mean(SD) VAS score for doctors' evaluation was 66.84(15.82) and 63.93(18.46) that of patients; ICC for agreement was 0.697 (0.672, 0.687 and 0.663 by age groups). CONCLUSIONS: An impact of age on HRQoL worsening is evidenced. Patient/doctor agreement in the evaluation of HRQoL is adequate; however doctors trend to overestimate the HRQoL of patients.

Heterogeneous Preferences For Delaying Onset Of Alzheimer’s Disease Among Older Adults In The Us

Value in Health, 2016

Factors and situations affecting the utility of patient preference studies: semi-structured interviews in Europe and the US

Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical ... more Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical industry, regulatory authorities, and health technology assessment (HTA) bodies/payers for use in assessments and decision-making along the medical product lifecycle (MPLC). This study aimed to identify factors and situations that influence the value of patient preference studies (PPS) in decision-making along the MPLC according to diff

Compendium Of Methods For Measuring Patient Preferences In Medical Treatment

Value in Health, 2017

alternatives (0.67), and side-effects (0.59). Costs per patient per year (0.58), budget impact (0... more alternatives (0.67), and side-effects (0.59). Costs per patient per year (0.58), budget impact (0.49) and disease rarity (0.45) ranked lowest. Rituximab in RA and NHL attained the highest overall score (0.60 and 0.52 respectively) and bevacizumab in MBC and NSCLC the lowest (0.46 and 0.40 respectively). The overall score of rituximab in RA was mainly attributable to high performance scores for disease severity, side-effects, and costs per patient per year. ConClusions: MCDA can facilitate reimbursement decision making as it quantifies both an overall score of each alternative and the relative importance of multiple criteria. This study shows that disease burden and unmet need were valued more importantly than cost-criteria. This information may support policy makers in making trade-offs between potentially conflicting criteria in reimbursement decision making for expensive drugs PHP188 ComParative effeCtiveness and safety of mediCal abortion for seCond-trimester PregnanCy termination: a systematiC review and network meta-analysis

Conditions And Contextual Factors That Influence The Utility And Application Of Patient Preference Studies: A Study Combining Literature And Focus Groups

Value in Health, Oct 1, 2017

Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review

Drug Discovery Today, 2019

Preference studies are becoming increasingly important within the medical product decision-making... more Preference studies are becoming increasingly important within the medical product decision-making context. Currently, there is limited understanding of the range of methods to gain insights into patient preferences. We developed a compendium and taxonomy of preference exploration (qualitative) and elicitation (quantitative) methods by conducting a systematic literature review to identify these methods. This review was followed by analyzing prior preference method reviews, to cross-validate our results, and consulting intercontinental experts, to confirm our outcomes. This resulted in the identification of 32 unique preference methods. The developed compendium and taxonomy can serve as an important resource for assessing these methods and helping to determine which are most appropriate for different research questions at varying points in the medical product lifecycle.

Architecture-dependent properties of analysis multirate filter banks

[Proceedings] ICASSP 91: 1991 International Conference on Acoustics, Speech, and Signal Processing, 1991

ABSTRACT Analysis multirate filter banks (MRBs) are implemented with parallel, hierarchic, serial... more ABSTRACT Analysis multirate filter banks (MRBs) are implemented with parallel, hierarchic, serial, and other architectures. The architectures vary widely in their properties. The authors generalize these architectures by defining a space of hybrid MRB architectures in which each member has different degrees of parallel, hierarchic, and serial processing. The authors calculate tradeoffs in processing time and hardware as a function of the architecture. On SISD (single instruction stream, single data stream) machines with direct form filters, they show that processing time decreases as the architecture becomes more hierarchic. Making the MRB more parallel only slightly lessens the time. With time-varying filters, making the MRB either more hierarchic or more parallel reduces the time. On hardwired machines, there is a parabolic tradeoff between processing time and hardware

PNS386 Patient Preferences in the Medical Product Lifecycle: Initial Results from the Imi Prefer Public-Private Project

Value in Health, 2019

Results: 527 interviews have been conducted up to May 2019. The average age was 49 (SD=16) and 41... more Results: 527 interviews have been conducted up to May 2019. The average age was 49 (SD=16) and 41% of respondents were male. 71.7% of respondents reported having no problems in the mobility dimension, 86.3% in the self-care dimension and 77.2% in the usual activities domain. 51.6% of the sample reported no problems with pain/ discomfort and 70% were neither depressed nor anxious. The mean value for the EQ-VAS was 81.4, SD=14.4. The preliminary model for EQ-5D-3L yielded values from 1 to -0.1, mean 0.55 (SD=0.2). The preliminary main effects hybrid model for EQ-5D-5L provided utility scores ranging from 0.33 (health state 55555) to 1 (health state 11111), mean 0.76 (SD=0.1). Conclusions: These preliminary results can support reimbursement decisions in Romania and allow regional cross-country comparisons. Once completed, this study will provide the largest data set on health-related quality of life in Romania and lay a stepping stone in the development of a health-technology assessment process more driven by locally relevant data.

PCV124 Reporting and Quality of Patient Preference Studies: A Systematic Literature Review in the Cardiovascular Domain

Value in Health, 2019

PCN25 a Benefit Risk Assessment of Laparoscopic Versus Open Rectal Surgical Resection for Cancer

Value in Health, 2019

Something is Better Than Nothing: The Value of Active Intervention on Stated Preferences for Treatments to Delay Onset of Alzheimer’s Disease Symptoms

Value in Health, 2018

PRM218 - Characterising and Appraising Patient Preference Exploration and Elicitiation Methods in the Medical Product Lifecycle

Value in Health, 2018

Structured Approaches to Benefit-Risk Assessment

Therapeutic Innovation & Regulatory Science, 2014

ABSTRACT

Identifying And Valuing Patient Group Engagement Methods

Value in Health, 2016

Publications not referring to observational studies, duplicates and review/discussion papers were... more Publications not referring to observational studies, duplicates and review/discussion papers were excluded. Key data abstracted included country, biosimilar/reference products, therapeutic area, study design, number of patients/sites, follow-up period, and outcomes of interest. Results: Of 188 abstracts reviewed, 17 met inclusion criteria. Fifteen studies (88%) were conducted in the European Union (EU) (Italy/France/Germany/Spain/other) and two (12%) outside EU. Therapeutic areas included chemotherapy-induced febrile neutropenia (n= 7), chronic kidney disease/anaemia (n= 4), chemotherapy-induced anaemia (n= 2), and other (n= 5). Filgrastim was the most frequent reference drug (n= 8) with 3 different biosimilars cited. Erythropoiesis Stimulating Agents (ESA) appeared in 5 studies with 2 different biosimilars. Infliximab (n= 1) and somatropin (n= 1) were cited with two and one biosimilars, respectively. Follow-up time ranged from 12 weeks to 10 years. All but two studies were regulator-mandated. Distribution by study design was: twelve (70%) prospective, three (18%) retrospective, one (6%) survey, and one (6%) registry. Outcomes included safety (n= 16), effectiveness (n= 16), patterns of care (n= 6), HRU (n= 3), physicians' perspective (n= 2), and Quality of Life (QoL) (n= 1). All studies (n= 11) reporting results on effectiveness/safety of a biosimilar found it in line with reference product. ConClusions: Almost all observational studies of biosimilars were mandated by regulators in the EU (wherebiosimilars were approved first) and assessed real-world safety and effectiveness.. Study infrastructures were often leveraged by including other outcomes (HRU, QoL), allowing the generation of realworld health economic and outcome evidence.

Patients’ Priorities For Treatment In Severe Asthma

Value in Health, 2015

To be eligible, studies had to focus on asthmatic patients, include pulmonary or eosinophil measu... more To be eligible, studies had to focus on asthmatic patients, include pulmonary or eosinophil measurements, and quality of life data. Results: The review allowed retrieving 5,776 studies and 42 fulfilled the eligibility criteria. Twenty-five articles presented a correlation coefficient between lung function and quality of life. All, except one, conclude to a positive correlation between lung function and quality of life with R-values ranging from 0.008 to 0.790. Of the 25 studies, 36% obtained an R-value of 0.4 and over, indicating a weak to moderate correlation. Sixteen of these results were statistically significant. One article evaluated the correlation between sputum eosinophil levels and AQLQ and concluded to a non-statistically significant correlation with an R-value of -0.15. Fourteen articles did not evaluate the direct correlation between the parameters of interest but presented raw data of these parameters. Of these, 12 studies presented data that indicate a correlation between FEV1 and quality of life with an increase in quality of life score, when FEV1 increases. ConClusions: The correlation coefficients found in the systematic review indicate that when lung function improves, and possibly when sputum eosinophil decreases, the quality of life improves. Furthermore, non-correlation studies that look at the same parameters support this hypothesis.

Case 2 best-worst scaling: For good or for bad but not for both

Journal of Choice Modelling, 2021

Abstract This paper studies the performance of case 2 best-worst scaling (BWS) when it is applied... more Abstract This paper studies the performance of case 2 best-worst scaling (BWS) when it is applied to a mix of positive and negative attributes, for example in studying treatments characterized by both benefits and harms. Intuitively, such a mix of positive and negative attributes leads to dominance. We analytically show that dominance leads to infinitely large differences between the parameter estimates for the positive versus negative attributes. The results from a simulation study confirm our analytical results: parameter values of the attributes could not be accurately recovered. When only a single positive attribute was used, even the relative ordering of the attribute level preferences was not identified. As a result, case 2 BWS can be used to elicit preferences if only good (positive) or only bad (negative) attributes are included in the choice tasks, but not for both since dominance will impact parameter estimation and therefore decision-making.

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US

Frontiers in Pharmacology, 2019

Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical ... more Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical industry, regulatory authorities, and health technology assessment (HTA) bodies/payers for use in assessments and decision-making along the medical product lifecycle (MPLC). This study aimed to identify factors and situations that influence the value of patient preference studies (PPS) in decision-making along the MPLC according to different stakeholders. Methods: Semi-structured interviews (n = 143) were conducted with six different stakeholder groups (physicians, academics, industry representatives, regulators, HTA/ payer representatives, and a combined group of patients, caregivers, and patient representatives) from seven European countries (the United Kingdom,

Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison

BMC Medical Informatics and Decision Making, 2020

BackgroundIncorporating patient preference (PP) information into decision-making has become incre... more BackgroundIncorporating patient preference (PP) information into decision-making has become increasingly important to many stakeholders. However, there is little guidance on which patient preference assessment methods, including preference exploration (qualitative) and elicitation (quantitative) methods, are most suitable for decision-making at different stages in the medical product lifecycle (MPLC). This study aimed to use an empirical approach to assess which attributes of PP assessment methods are most important, and to identify which methods are most suitable, for decision-makers’ needs during different stages in the MPLC.MethodsA four-step cumulative approach was taken: 1) Identify important criteria to appraise methods through a Q-methodology exercise, 2) Determine numerical weights to ascertain the relative importance of each criterion through an analytical hierarchy process, 3) Assess the performance of 33 PP methods by applying these weights, consulting international healt...

Stakeholder Perspectives On The Integration Of Patient Preferences In The Medical Product Life Cycle: A Multimethod Approach

Value in Health, Oct 1, 2017

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

The Patient - Patient-Centered Outcomes Research, 2019

Background Patient preferences (PP), which are investigated in PP studies using qualitative or qu... more Background Patient preferences (PP), which are investigated in PP studies using qualitative or quantitative methods, are a growing area of interest to the following stakeholders involved in the medical product lifecycle: academics, health technology assessment bodies, payers, industry, patients, physicians, and regulators. However, the use of PP in decisions along the medical product lifecycle remains limited. As the adoption of PP heavily relies on these stakeholders, knowledge of their perceptions of PP is critical. Objective This study aimed to characterize stakeholders' attitudes, needs, and concerns with respect to PP in decision making along the medical product lifecycle. Methods Semi-structured interviews (n = 143) were conducted with academics (n = 24), health technology assessment/ payer representatives (n = 24), industry representatives (n = 24), patients, caregivers and patient representatives (n = 24), physicians (n = 24), and regulators (n = 23) from seven European countries and the USA. Interviews were conducted between April and August 2017. The framework method was used to organize the data and identify themes and key findings in each interviewed stakeholder group. Results Interviewees reported being unfamiliar (43%), moderately familiar (42%), or very familiar (15%) with preference methods and studies. Interviewees across stakeholder groups generally supported the idea of using PP in the medical product lifecycle but expressed mixed opinions about the feasibility and impact of using PP in decision making. Interviewees from all stakeholder groups stressed the importance of increasing stakeholders' understanding of the concept of PP and preference methods and ensuring patients' understanding of the questions asked in PP studies. Key concerns and needs in each interviewed stakeholder group were as follows: (1) academics: investigating the validity, reliability, reproducibility, and generalizability of preference methods; (2) health technology assessment/payer representatives: developing quality criteria for evaluating PP studies and gaining insights into how to weigh them in reimbursement/payer decision making; (3) industry representatives: obtaining guidance on PP studies and recognition on the importance of PP from decision makers; (4) patients, caregivers, and patient representatives: providing an incentive and adequate information towards patients when Jorien Veldwijk and Isabelle Huys are joint last author. Disclaimer: This text and its contents reflect the PREFER project's view and not the view of the Innovative Medicines Initiative, the European Union, or the European Federation of Pharmaceutical Industries and Associations.

PCV101 Japanese Patients and Physicians Preferences for Anticoagulants Use in Atrial Fibrillation - Results From a Conjoint-Analysis Study

Value in Health, 2012

OBJECTIVES: To analyse the association between Health Related Quality of Life (HRQoL) and age, in... more OBJECTIVES: To analyse the association between Health Related Quality of Life (HRQoL) and age, in hypertensive patients and the correlation between HRQoL reported by patients and evaluated by their doctors. METHODS: Observational, cross-sectional, multi-centre study, in Primary and Specialised Care. Inclusion of 5,031 hypertensive patients, selected by quotes according to three age groups (Ͻ65, 65-79, Ն 80 years) was planned. Selection criteria were: patients whose age was over 18, diagnosed as having hypertension at least one year before inclusion and attended a follow-up visit. Information related to hypertension, basic socio-demographic and clinical data, the self-administered specific questionnaire MINICHAL for the evaluation of HRQoL (higher scores indicative of lower HRQoL), and a visual analogue scale (VAS) for the general evaluation of HRQoL (higher scores indicative of higher HRQoL) by patients and doctors, were recorded. Data of 4,346 eligible patients were included. HRQoL-age correlation was analysed by Spearman's-rho, differences among age groups by Kruskal-Wallis and patient/doctor agreement by the intraclass correlation coefficient (ICC). RESULTS: Mean age (SD) was 68.35(12.60). 38.1% of patients were under 65, 36.9% between 65 and 80 and 25.0% were over 80 years old. 54.5% were men. Mean time since diagnosis was 10.33(7.68) years. 34.2% had a family history of high blood pressure. Mean scores in MINICHAL were: State of Mind dimension 8.07(5.83), Somatic Manifestations dimension 3.24(3.06). Worsening of both dimensions was found when comparing groups of higher age (pϽ0.001) as well as significant moderate correlations of both dimensions with age (0.335, pϽ0.001; 0.397 pϽ0.001). Mean(SD) VAS score for doctors' evaluation was 66.84(15.82) and 63.93(18.46) that of patients; ICC for agreement was 0.697 (0.672, 0.687 and 0.663 by age groups). CONCLUSIONS: An impact of age on HRQoL worsening is evidenced. Patient/doctor agreement in the evaluation of HRQoL is adequate; however doctors trend to overestimate the HRQoL of patients.

Heterogeneous Preferences For Delaying Onset Of Alzheimer’s Disease Among Older Adults In The Us

Value in Health, 2016

Factors and situations affecting the utility of patient preference studies: semi-structured interviews in Europe and the US

Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical ... more Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical industry, regulatory authorities, and health technology assessment (HTA) bodies/payers for use in assessments and decision-making along the medical product lifecycle (MPLC). This study aimed to identify factors and situations that influence the value of patient preference studies (PPS) in decision-making along the MPLC according to diff

Compendium Of Methods For Measuring Patient Preferences In Medical Treatment

Value in Health, 2017

alternatives (0.67), and side-effects (0.59). Costs per patient per year (0.58), budget impact (0... more alternatives (0.67), and side-effects (0.59). Costs per patient per year (0.58), budget impact (0.49) and disease rarity (0.45) ranked lowest. Rituximab in RA and NHL attained the highest overall score (0.60 and 0.52 respectively) and bevacizumab in MBC and NSCLC the lowest (0.46 and 0.40 respectively). The overall score of rituximab in RA was mainly attributable to high performance scores for disease severity, side-effects, and costs per patient per year. ConClusions: MCDA can facilitate reimbursement decision making as it quantifies both an overall score of each alternative and the relative importance of multiple criteria. This study shows that disease burden and unmet need were valued more importantly than cost-criteria. This information may support policy makers in making trade-offs between potentially conflicting criteria in reimbursement decision making for expensive drugs PHP188 ComParative effeCtiveness and safety of mediCal abortion for seCond-trimester PregnanCy termination: a systematiC review and network meta-analysis

Conditions And Contextual Factors That Influence The Utility And Application Of Patient Preference Studies: A Study Combining Literature And Focus Groups

Value in Health, Oct 1, 2017

Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review

Drug Discovery Today, 2019

Preference studies are becoming increasingly important within the medical product decision-making... more Preference studies are becoming increasingly important within the medical product decision-making context. Currently, there is limited understanding of the range of methods to gain insights into patient preferences. We developed a compendium and taxonomy of preference exploration (qualitative) and elicitation (quantitative) methods by conducting a systematic literature review to identify these methods. This review was followed by analyzing prior preference method reviews, to cross-validate our results, and consulting intercontinental experts, to confirm our outcomes. This resulted in the identification of 32 unique preference methods. The developed compendium and taxonomy can serve as an important resource for assessing these methods and helping to determine which are most appropriate for different research questions at varying points in the medical product lifecycle.

Architecture-dependent properties of analysis multirate filter banks

[Proceedings] ICASSP 91: 1991 International Conference on Acoustics, Speech, and Signal Processing, 1991

ABSTRACT Analysis multirate filter banks (MRBs) are implemented with parallel, hierarchic, serial... more ABSTRACT Analysis multirate filter banks (MRBs) are implemented with parallel, hierarchic, serial, and other architectures. The architectures vary widely in their properties. The authors generalize these architectures by defining a space of hybrid MRB architectures in which each member has different degrees of parallel, hierarchic, and serial processing. The authors calculate tradeoffs in processing time and hardware as a function of the architecture. On SISD (single instruction stream, single data stream) machines with direct form filters, they show that processing time decreases as the architecture becomes more hierarchic. Making the MRB more parallel only slightly lessens the time. With time-varying filters, making the MRB either more hierarchic or more parallel reduces the time. On hardwired machines, there is a parabolic tradeoff between processing time and hardware

PNS386 Patient Preferences in the Medical Product Lifecycle: Initial Results from the Imi Prefer Public-Private Project

Value in Health, 2019

Results: 527 interviews have been conducted up to May 2019. The average age was 49 (SD=16) and 41... more Results: 527 interviews have been conducted up to May 2019. The average age was 49 (SD=16) and 41% of respondents were male. 71.7% of respondents reported having no problems in the mobility dimension, 86.3% in the self-care dimension and 77.2% in the usual activities domain. 51.6% of the sample reported no problems with pain/ discomfort and 70% were neither depressed nor anxious. The mean value for the EQ-VAS was 81.4, SD=14.4. The preliminary model for EQ-5D-3L yielded values from 1 to -0.1, mean 0.55 (SD=0.2). The preliminary main effects hybrid model for EQ-5D-5L provided utility scores ranging from 0.33 (health state 55555) to 1 (health state 11111), mean 0.76 (SD=0.1). Conclusions: These preliminary results can support reimbursement decisions in Romania and allow regional cross-country comparisons. Once completed, this study will provide the largest data set on health-related quality of life in Romania and lay a stepping stone in the development of a health-technology assessment process more driven by locally relevant data.

PCV124 Reporting and Quality of Patient Preference Studies: A Systematic Literature Review in the Cardiovascular Domain

Value in Health, 2019

PCN25 a Benefit Risk Assessment of Laparoscopic Versus Open Rectal Surgical Resection for Cancer

Value in Health, 2019

Something is Better Than Nothing: The Value of Active Intervention on Stated Preferences for Treatments to Delay Onset of Alzheimer’s Disease Symptoms

Value in Health, 2018

PRM218 - Characterising and Appraising Patient Preference Exploration and Elicitiation Methods in the Medical Product Lifecycle

Value in Health, 2018

Structured Approaches to Benefit-Risk Assessment

Therapeutic Innovation & Regulatory Science, 2014

ABSTRACT

Identifying And Valuing Patient Group Engagement Methods

Value in Health, 2016

Publications not referring to observational studies, duplicates and review/discussion papers were... more Publications not referring to observational studies, duplicates and review/discussion papers were excluded. Key data abstracted included country, biosimilar/reference products, therapeutic area, study design, number of patients/sites, follow-up period, and outcomes of interest. Results: Of 188 abstracts reviewed, 17 met inclusion criteria. Fifteen studies (88%) were conducted in the European Union (EU) (Italy/France/Germany/Spain/other) and two (12%) outside EU. Therapeutic areas included chemotherapy-induced febrile neutropenia (n= 7), chronic kidney disease/anaemia (n= 4), chemotherapy-induced anaemia (n= 2), and other (n= 5). Filgrastim was the most frequent reference drug (n= 8) with 3 different biosimilars cited. Erythropoiesis Stimulating Agents (ESA) appeared in 5 studies with 2 different biosimilars. Infliximab (n= 1) and somatropin (n= 1) were cited with two and one biosimilars, respectively. Follow-up time ranged from 12 weeks to 10 years. All but two studies were regulator-mandated. Distribution by study design was: twelve (70%) prospective, three (18%) retrospective, one (6%) survey, and one (6%) registry. Outcomes included safety (n= 16), effectiveness (n= 16), patterns of care (n= 6), HRU (n= 3), physicians' perspective (n= 2), and Quality of Life (QoL) (n= 1). All studies (n= 11) reporting results on effectiveness/safety of a biosimilar found it in line with reference product. ConClusions: Almost all observational studies of biosimilars were mandated by regulators in the EU (wherebiosimilars were approved first) and assessed real-world safety and effectiveness.. Study infrastructures were often leveraged by including other outcomes (HRU, QoL), allowing the generation of realworld health economic and outcome evidence.

Patients’ Priorities For Treatment In Severe Asthma

Value in Health, 2015

To be eligible, studies had to focus on asthmatic patients, include pulmonary or eosinophil measu... more To be eligible, studies had to focus on asthmatic patients, include pulmonary or eosinophil measurements, and quality of life data. Results: The review allowed retrieving 5,776 studies and 42 fulfilled the eligibility criteria. Twenty-five articles presented a correlation coefficient between lung function and quality of life. All, except one, conclude to a positive correlation between lung function and quality of life with R-values ranging from 0.008 to 0.790. Of the 25 studies, 36% obtained an R-value of 0.4 and over, indicating a weak to moderate correlation. Sixteen of these results were statistically significant. One article evaluated the correlation between sputum eosinophil levels and AQLQ and concluded to a non-statistically significant correlation with an R-value of -0.15. Fourteen articles did not evaluate the direct correlation between the parameters of interest but presented raw data of these parameters. Of these, 12 studies presented data that indicate a correlation between FEV1 and quality of life with an increase in quality of life score, when FEV1 increases. ConClusions: The correlation coefficients found in the systematic review indicate that when lung function improves, and possibly when sputum eosinophil decreases, the quality of life improves. Furthermore, non-correlation studies that look at the same parameters support this hypothesis.